论文部分内容阅读
目的观察氯吡格雷联合阿司匹林治疗不稳定型心绞痛(UAP)的疗效及安全性。方法98例符合UAP诊断标准的患者,随机分为治疗组(50例)和对照组(48例)。对照组采用常规抗心绞痛治疗,应用肠溶阿司匹林片100 mg,1次/d。治疗组在对照组治疗基础上加服氯吡格雷75 mg,1次/d。两组持续口服用药,随访6个月。观察两组疗效、主要终点事件及不良反应发生情况。结果治疗3个月后治疗组和对照组心绞痛发生率分别为8.0%和29.2%,差异有统计意义(P<0.05);治疗6个月后治疗组和对照组心绞痛发生率分别为8.0%和29.2%,差异有统计学意义(P<0.01);随访6个月内治疗组和对照组急性心肌梗死(AMI)、死亡的发生率分别为0和10.5%,差异有统计学意义(P<0.01)。两组药物不良反应发生率比较差异无统计学意义(P>0.05)。结论氯吡格雷联合阿司匹林治疗UAP疗效优于单用阿司匹林治疗,且不良反应无增加,安全性好。
Objective To observe the efficacy and safety of clopidogrel combined with aspirin in the treatment of unstable angina pectoris (UAP). Methods A total of 98 patients with UAP diagnostic criteria were randomly divided into treatment group (50 cases) and control group (48 cases). The control group was treated with conventional anti-angina pectoris. The patients were given enteric-coated aspirin 100 mg once daily. The treatment group in the control group based on the plus clopidogrel 75 mg, 1 / d. The two groups continued oral medication, followed up for 6 months. The two groups were observed the efficacy, the main end point and adverse reactions. Results The incidence of angina pectoris in the treatment group and the control group after 3 months treatment was 8.0% and 29.2%, respectively, with statistical significance (P <0.05). After 6 months of treatment, the incidences of angina in the treatment group and the control group were 8.0% and 29.2%, the difference was statistically significant (P <0.01). The incidence of death in acute myocardial infarction (AMI) in treatment group and control group within 6 months after follow-up was 0 and 10.5% respectively, with significant difference (P < 0.01). There was no significant difference in the incidence of adverse drug reactions between the two groups (P> 0.05). Conclusion The efficacy of clopidogrel combined with aspirin in the treatment of UAP is better than that of aspirin alone, with no increase of adverse reactions and good safety.